There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Liquidia Technologies Inc (LQDA) and La Jolla Pharma (LJPC) with bullish sentiments.
Liquidia Technologies Inc (LQDA)
In a report released today, Liana Moussatos from Wedbush reiterated a Buy rating on Liquidia Technologies Inc, with a price target of $50. The company’s shares closed yesterday at $7.92, close to its 52-week low of $7.61.
According to TipRanks.com, Moussatos has 0 stars on 0-5 star ranking scale with an average return of -9.9% and a 30.8% success rate. Moussatos covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical Inc., Allena Pharmaceuticals Inc, and Aquestive Therapeutics Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Liquidia Technologies Inc with a $50 average price target.
See today’s analyst top recommended stocks >>
La Jolla Pharma (LJPC)
In a report released today, Edward White from H.C. Wainwright maintained a Buy rating on La Jolla Pharma, with a price target of $27. The company’s shares closed yesterday at $8.99, close to its 52-week low of $5.01.
White observed:
“We base our $27 price target on a sum-of-the-parts analysis derived from: (1) the P/E value of La Jolla’s current commercial business (Giapreza); (2) an NPV of its pipeline (LJPC-401); and (3) our estimated year-end 2019 fully diluted net cash of $2.03/share to arrive at our price target. We value the current commercial business at $12.94 per share and the pipeline at $11.99 per share. The commercial business value is based on a P/E multiple assumption of 30x our 2024E EPS of $0.75, discounted at 15%.”
According to TipRanks.com, White is a 5-star analyst with an average return of 19.4% and a 50.9% success rate. White covers the Healthcare sector, focusing on stocks such as Syndax Pharmaceuticals Inc, Aeglea Biotherapeutics Inc, and Spectrum Pharmaceuticals.
The word on The Street in general, suggests a Strong Buy analyst consensus rating for La Jolla Pharma with a $24 average price target, representing a 167.0% upside. In a report issued on June 24, Chardan Capital also maintained a Buy rating on the stock with a $20 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
